Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

(NasdaqGM:TRDA), – Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to progress into global clinical development in 2025 – BOSTON, March 24, 2025 (GLOBE […]

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

(NasdaqGM:AURA), Clinical Complete Responses Observed with Single Low-Dose of Bel-sar in Patients with Intermediate and High-Risk NMIBC with Robust Cell-Mediated Immunity and Urothelial Field Effect Favorable Safety Profile; Only Grade 1 Drug-Related Adverse Events Reported in Less Than 10% of Patients Data Supports Potential for a Paradigm Shifting Approach in the Front-Line Treatment of patients

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

(NASDAQ:VERV), BOSTON, March 24, 2025 (GLOBE NEWSWIRE) — Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for VERVE-102 for the treatment of patients living with heterozygous familial hypercholesterolemia (HeFH)

Kevin Kearney Joins Lungpacer Medical as Chief Commercial Officer

EXTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) — Lungpacer Medical today announced the appointment of Kevin Kearney as Chief Commercial Officer (CCO). Kearney brings over 20 years of commercial leadership, business development, and strategic sales operations experience in the medical device and healthcare industries. His appointment marks a significant milestone as the company expands its

How CNH’s precision technology is helping farmers tackle water scarcity

(NYSE:CNHI),(Milan:CNHI), How CNH's precision technology is helping farmers tackle water scarcity Basildon, March 24, 2025 Following World Water Day on March 22, CNH brands – Case IH and New Holland – continue to lead the way in breaking new ground in precision agriculture. As part of the Drops of the Future initiative, CNH has teamed

Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round

Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investors Proceeds to support the clinical development of lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth (CMT) disease, with Phase I trials starting imminently Pipeline of

Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference

(NASDAQ:KTTA),(NASDAQ:KTTAW), — Conference taking place on March 27-29, 2025 in New Orleans — — CAGLA NeauxCancer Conference is a leading global forum in oncology — MIAMI, March 24, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment

Power Knot Ocean Delivers LFC Biodigester for MS Seaventure

Power Knot Ocean, the market leader for onboard organic waste management solutions in the marine environment, is pleased to announce the installation of an LFC-200biodigester aboard the expedition vessel MS Seaventure. Seaventure's operators have prioritized sustainability by selecting the LFC biodigester to enhance waste management and ensure compliance with stringent environmental regulations in sensitive waters

TISE reports record turnover, profit & EPS for 2024

2024 financial year highlights at TISE — Record turnover of £13.3 million – up 22.6% year on year — Profit increased 24.2% year on year to a new high of £6.0 million — Earnings per share increased to 212.7p; £9.1 million returned to shareholders during 2024 — 952 new listings contributed to overall public market

A Quarter Century of Gorgeous: Quo Beauty® Turns 25!

Iconic Canadian Brand Quo Beauty® Celebrates 25 Years of Creativity and Self-Expression Today, Quo Beauty®, the beloved & multi-award-winning Canadian beauty brand owned by Shoppers Drug Mart, is celebrating a milestone birthday. For 25 years,Quo Beauty has been a beauty lover's trusted BFF, bringing Canadians the hottest trends and must-have products at exceptional value. “25

Scroll to Top